Agoracom Blog Home

Posts Tagged ‘Medical Marijuana stocks’

Tetra Bio-Pharma Announces the Initiation of its Phase I Trial of dried Cannabis $TBP.ca

Posted by AGORACOM-JC at 8:45 AM on Thursday, February 23rd, 2017

Tbp large

  • Announces launch of its Double-Blind Phase I Study to Assess Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Single and Multiple Daily Ascending Doses of Cannabis (Delta-9-tetrahydrocannabinol/ Cannabidiol) by Smoking/Inhalation in Healthy Male and Female Volunteers
  • Phase I clinical research is a classical pharmaceutical study in the development of a new drug. The trial activities will occur over a 3 to 4-month period and involve site initiation, subject recruitment and enrolment, a single daily ascending dose phase and a 7-day multiple daily ascending dose phase, followed by study termination

OTTAWA, ONTARIO–(Feb. 23, 2017) – PhytoPain Pharma (PPP), a subsidiary of Tetra BioPharma Inc. (“Tetra” or the “Company“) (CSE:TBP)(CSE:TBP.CN)(OTC PINK:GRPOF), a pharmaceutical company focused on developing and commercializing therapeutic cannabis-based products for the treatment of pain is pleased to announce the launch of its Double-Blind Phase I Study to Assess Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Single and Multiple Daily Ascending Doses of Cannabis (Delta-9-tetrahydrocannabinol/ Cannabidiol) by Smoking/Inhalation in Healthy Male and Female Volunteers.

The Phase I clinical research is a classical pharmaceutical study in the development of a new drug. The trial activities will occur over a 3 to 4-month period and involve site initiation, subject recruitment and enrolment, a single daily ascending dose phase and a 7-day multiple daily ascending dose phase, followed by study termination. Algorithme Pharma has already begun recruiting subjects for the Phase I trial. This study is a pivotal safety trial as it will allow Tetra to understand the adverse effects of smoking Cannabis and associate the outcomes, such as cognitive function, to plasma levels of THC and CBD. The study will provide Tetra with the data necessary to discuss with Health Canada and FDA the potential risks in patient populations and discuss marketing requirements for specific indications.

The pharmacokinetic profile and safety data generated by the Phase I trial will allow Tetra to finalize the design of its Phase II-III clinical trial that will assess the safety and efficacy of PPP001 in cancer patients with uncontrolled pain. PPP001 is being developed for cancer patients with moderate-to-severe pain and that are not adequately controlled with the standard of care. Approximately 50% of cancer patients suffer from pain and more than 600,000 of these patients suffer from moderate-to-severe pain. In the USA, there are over 4 million cancer patients and this pain market is valued at over $5 billion USD.

We are very pleased to announce that the start of the Phase I clinical trial activities as this keeps the company on track in its development of PPP001″, commented Mr, Andre Rancourt. “With PPP001 and the mucoadhesive AdVersa® controlled-release tablet, Tetra is positioning itself to become a major player in the cancer pain therapy market, added Mr. Rancourt.

The Canadian Securities Exchange (“CSE”) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Dr. Guy Chamberland
Chief Science Officer
(514) 220-9225

 

INTERVIEW: Tetra Bio-Pharma Developing Pharma Derived From Cannabis and Other Medicinal Plants $TBP.ca

Posted by AGORACOM-JC at 11:41 AM on Tuesday, November 8th, 2016

Pharmaceutical Division – PhytoPain Pharma

  • Developing and commercialization of botanical based pharmaceuticals
  • Engaged in the development of medication to alleviate symptoms related to: Pain, Insomnia, anxiety disorder, in patients suffering from Cancer and other, chronic and terminal diseases

Recent Highlights

  • Signed a Supply Agreement with Access to Cannabis for Medical Purpose Regulations (“ACMPR”) licensed producer Aphria Inc.
  • For the supply of dried medical cannabis as an Active Pharmaceutical Ingredient (API) for PPP’s inhalation cannabis product PPP001
  • Acquired multiple intellectual property assets related to the initiation of manufacturing and distribution of products for natural health care including products containing extracts or oils derived from Cannabis sativa
  • Recently announced awarding of the NSERC Engage partnership grant with McGill University will allow AGTK to achieve its commercial strategy to launch Cannabis-derived supplements that comply with the existing regulations regarding cannabis and cannabinoid content

Hub On AGORACOM / Corporate Profile / Watch Interview

FEATURE: GrowPros (GCI:CSE) Natural Pharmaceuticals From Cannabis and Other Medicinal Plants $GCI.ca

Posted by AGORACOM-JC at 3:52 PM on Wednesday, August 10th, 2016

Growpros_hub_large

Natural Pharmaceuticals Derived From Cannabis and Other Medicinal Plants

Comprised Of Two Divisions

Pharmaceutical Division – PhytoPain Pharma

  • A new subsidiary created June 2, 2016. 80% Ownership
  • Mission is the development and commercialization of botanical based pharmaceuticals
  • A clinical stage drug development company engaged in the development of medication to alleviate symptoms related to: Pain,
    Insomni, anxiety disorder, in patients suffering from Cancer and othe, chronic and terminal diseases

Dr Guy Chamberland, Chief Scientific Officer and Regulatory Affairs

  • Professor of herbal medicine and clinical research at the École d’Enseignement Supérieur de Naturopathie du Québec.
  • 22 years’ experience in the pharmaceutical and natural product industries includes successful development of intellectual property for several botanical drug products

WHY DOCTORS NEED PHARMA MARIJUANA SOLUTIONS

  • A Physician’s decision to prescribe a new drug or even a natural health product has to be based on Evidence-Based Medicine > A legal, ethical requirement
  • Currently, no body of evidence exists to not support the prescription or recommendation of medical marijuana in any medical condition, including terminal cancer
  • The GrowPros pharmaceutical product development plan would provide the data necessary for physicians to prescribe or recommend our products

PRODUCT PIPELINE

Insomnia Management For Patients With Chronic Pain

  • Licensed a hypnotic drug from Mondias Naturals Inc
  • Management of Insomnia in patients with chronic pain
  • Currently in late stage Phase III clinical testing

PhytoPain To Produce A Combination Product

  • Proprietary combination expected to reach Phase I clinical testing in 2017
  • Will be ready for market in 2017 due to combination with Mondias Naturals product

Pain Management – Inhalation Cannabis Drug Product

  • A prescription drug for management of uncontrolled pain in cancer patients
  • Health Canada will provide guidance during Phase I clinical trial
  • Commencing December 2016. Anticipating 3-5 year product development

A recent discussion with the Quebec College of Physicians confirms that pharmaceutical development of a medical marijuana for inhalation would be well received by the medical community.

OPERATIONS OVERVIEW – MMPR

MMPR Division – Collaboration Agreement

  • March 18, 2016 – Signed agreement with Delta 9 Bio-Tech, a “Licensed Producer”
  • Delta 9 will submit to Health Canada an Amendment to collaborate on GrowPros previous application for facility in Southern Quebec; Amendment submission anticipated by June 30, 2106, Health Canada response anticipated August 30, 2016
  • Key Benefits of Delta 9 Collaboration: Significant process clarity, High probability of success eliminates spec construction risk, Single customer through option to acquire all dried marijuana product for 2 years
  • Key strategic benefit to GrowPros; Controlled production, quality and supply for Pharma Division, Value of license, Wholesale seller vs. retail seller

12 Month Stock Chart

CLIENT FEATURE: GrowPros (GCI: CSE) Natural Pharmaceuticals Derived From Cannabis and Other Medicinal Plants $GCI.ca

Posted by AGORACOM-JC at 4:37 PM on Wednesday, July 27th, 2016

Growpros_hub_large

Comprised Of Two Divisions

Pharmaceutical Division – PhytoPain Pharma

  • A new subsidiary created June 2, 2016. 80% Ownership
  • Mission is the development and commercialization of botanical based pharmaceuticals
  • A clinical stage drug development company engaged in the development of medication to alleviate symptoms related to: Pain,
    Insomni, anxiety disorder, in patients suffering from Cancer and othe, chronic and terminal diseases

Dr Guy Chamberland, Chief Scientific Officer and Regulatory Affairs

  • Professor of herbal medicine and clinical research at the École d’Enseignement Supérieur de Naturopathie du Québec.
  • 22 years’ experience in the pharmaceutical and natural product industries includes successful development of intellectual property for several botanical drug products

WHY DOCTORS NEED PHARMA MARIJUANA SOLUTIONS

  • A Physician’s decision to prescribe a new drug or even a natural health product has to be based on Evidence-Based Medicine > A legal, ethical requirement
  • Currently, no body of evidence exists to not support the prescription or recommendation of medical marijuana in any medical condition, including terminal cancer
  • The GrowPros pharmaceutical product development plan would provide the data necessary for physicians to prescribe or recommend our products

PRODUCT PIPELINE

Insomnia Management For Patients With Chronic Pain

  • Licensed a hypnotic drug from Mondias Naturals Inc
  • Management of Insomnia in patients with chronic pain
  • Currently in late stage Phase III clinical testing

PhytoPain To Produce A Combination Product

  • Proprietary combination expected to reach Phase I clinical testing in 2017
  • Will be ready for market in 2017 due to combination with Mondias Naturals product

Pain Management – Inhalation Cannabis Drug Product

  • A prescription drug for management of uncontrolled pain in cancer patients
  • Health Canada will provide guidance during Phase I clinical trial
  • Commencing December 2016. Anticipating 3-5 year product development

A recent discussion with the Quebec College of Physicians confirms that pharmaceutical development of a medical marijuana for inhalation would be well received by the medical community.

OPERATIONS OVERVIEW – MMPR

MMPR Division – Collaboration Agreement

  • March 18, 2016 – Signed agreement with Delta 9 Bio-Tech, a “Licensed Producer”
  • Delta 9 will submit to Health Canada an Amendment to collaborate on GrowPros previous application for facility in Southern Quebec; Amendment submission anticipated by June 30, 2106, Health Canada response anticipated August 30, 2016
  • Key Benefits of Delta 9 Collaboration: Significant process clarity, High probability of success eliminates spec construction risk, Single customer through option to acquire all dried marijuana product for 2 years
  • Key strategic benefit to GrowPros; Controlled production, quality and supply for Pharma Division, Value of license, Wholesale seller vs. retail seller

Hub On AGORACOM /Corporate Profile

Enertopia Provides Canadian Medical Marihuana Update

Posted by AGORACOM-JC at 11:00 AM on Friday, June 12th, 2015

  • Signed a binding LOI to sell its wholly owned sub Thor Pharma Corp along with the MMPR application number 10MMPR0610
  • Burlington MMPR license application will continue in the application process under new ownership
  • Joint Venture could receive up to $1,500,000 in milestone payments upon the Burlington facility becoming licensed under the MMPR program

VANCOUVER, BC / June 12 2015 – Enertopia Corporation (ENRT-OTCBB) (TOP-CSE) (the “Company” or “Enertopia”) announces updates with respect to the Burlington and The Green Canvas Joint Ventures.

Enertopia has signed a binding LOI to sell its wholly owned sub Thor Pharma Corp along with the MMPR application number 10MMPR0610. The Burlington MMPR license application will continue in the application process under new ownership. The Joint Venture could receive up to $1,500,000 in milestone payments upon the Burlington facility becoming licensed under the MMPR program. These monies would be split approximately 50% with Lexaria Corp. Subsequent with this deal the Burlington Joint Venture between Enertopia and Lexaria which was entered into on May 27, 2014 has been terminated due to the pending sale of the project. The Enertopia and Lexaria Master Joint Venture Agreement entered into on March 5, 2014 is still in good standing as both companies continue to look at synergistic opportunities to increase shareholder value.

After thorough examination of the Medical Marihuana industry in Canada and current participants within the sector, it is apparent that raising capital to push projects forward is not currently in the best interests of the Company. Therefore, the Company and The Green Canvas have mutually agreed to terminate their Joint Venture and 6,400,000 shares of Enertopia held in escrow with respect to The Green Canvas Joint Venture will be returned back to corporate treasury and cancelled.

Enertopia is and will continue to be an advocate for medical cannabis for patients and applauds the landmark Supreme Court of Canada ruling on June 11, 2015. This ruling upheld the rights of legal MMAR and MMPR medical cannabis patients in Canada. The unanimous ruling allows valid legal medical patients to choose how they want to administer medical cannabis by the method that is best suited to their medical condition and body absorption. This is looks to be a very positive development for the Canadian medical marihuana sector going forward, as the Federal Government will have to modify or implement a program for the administration of other forms of medical cannabis consumption.

Enertopia will continue to look for opportunities in the MMJ and other sectors that offer the best return for all stakeholders with the least amount of dilution to the Company. The Company looks forward to utilizing its learned knowledge in the MMJ sector and will continue on its path of becoming a licensed producer.

“The Company has completed two milestones in building a stable foundation with its ownership of 1,000,000 shares in Lexaria Corp which has just filed PCT for patent pending bio technologies and the potential of approximately $750,000 in future payments from the Burlington application,” Stated President Robert McAllister

The Company looks forward to providing information via social media, website and press releases as news and events become known over the coming weeks.

About Enertopia

We are a company with the mission to empower people with a better way of living through healthy lifestyle choices in helping you live your life your way. Our core values of honesty, integrity, and commitment help to define our corporate practices and demonstrate our dedication in helping individuals whether they are encountering health issues based on age, diet or have suffered a traumatic physical, mental or an emotional event.

Enertopia’s shares are quoted in Canada with symbol TOP and in the United States with symbol ENRT. For additional information, please visit www.enertopia.com or call Robert McAllister, the President: (250) 765-6412

This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, potential and financing of its medical marihuana projects, evaluation and sale of sexual creams and other items, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions that are forward-looking statements. Such forward-looking statements are estimates reflecting the Company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements., foreign exchange and other financial markets; changes of the interest rates on borrowings; hedging activities; changes in commodity prices; changes in the investments and exploration expenditure levels; litigation; legislation; environmental, judicial, regulatory, political and competitive developments in areas in which Enertopia Corporation operates. The User should refer to the risk disclosures set out in the periodic reports and other disclosure documents filed by Enertopia Corporation from time to time with regulatory authorities. There is no assurance that the Company will receive any milestone payments from the sale of Thor Pharma and the Burlington MMPR application, or that the 1,000,000 shares of Lexaria Corp will have any meaningful impact on the Company or the Company will be able to obtain future financings or a license under the MMPR program.

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release

Medical marijuana includes cookies, brownies, oils and tea rules Supreme Court

Posted by AGORACOM-JC at 11:33 AM on Thursday, June 11th, 2015

The Supreme Court of Canada has ruled that limiting medical consumption to dried marijuana infringes on liberty protections under the Charter of Rights.Cannabis-infused peanut butter cookies are displayed for sale at a Weeds Glass and Gifts medical marijuana dispensary in downtown Vancouver, B.C.

DARRYL DYCK / THE CANADIAN PRESS

Cannabis-infused peanut butter cookies are displayed for sale at a Weeds Glass and Gifts medical marijuana dispensary in downtown Vancouver, B.C.

By: The Canadian Press, Published on Thu Jun 11 2015

OTTAWA—The Supreme Court of Canada says medical marijuana can include products other than dried pot, such as cannabis-infused cookies brownies, oils and tea.

The court has rejected an appeal by the federal government of a lower court ruling that medical marijuana users have a right to a range of products containing the drug.

In a 7-0 decision, the court ruled that limiting medical consumption to dried marijuana infringes on liberty protections under the Charter of Rights.

Current federal regulations stipulate that authorized users of physician-prescribed cannabis can only consume dried marijuana.

The case stems from the arrest in 2009 of Owen Smith, former head baker for the Cannabis Buyers Club of Canada, who was charged after police found more than 200 pot cookies and cannabis-infused olive oil and grapeseed oil in his Victoria apartment.

Private insurer covers medical marijuana costs

Posted by AGORACOM-JC at 11:18 AM on Monday, March 23rd, 2015

A university student’s medical marijuana is being paid for by his private insurance company – a feat some industry insiders say is unprecedented.

Sun Life Financial is covering the medical marijuana costs of University of Waterloo student Jonathan Zaid.

Peter Power / For The Toronto Star

Sun Life Financial is covering the medical marijuana costs of University of Waterloo student Jonathan Zaid.

By: Isabel Teotonio Living reporter, Published on Fri Mar 20 2015

After a hard-fought battle, Jonathan Zaid’s medical marijuana is being paid for by his private insurance company — a feat some industry insiders say is unprecedented.

Now, the third-year University of Waterloo student, who suffers from a rare illness called new daily persistent headache, is hoping this victory clears the way for other patients seeking coverage for cannabis.

“I had to fight a lot of battles to get to where I am,” says the 22-year-old Toronto native. “My persistence paid off in the end.”

Last summer, Zaid submitted a claim for his medical marijuana to insurance giant Sun Life Financial. It was denied. Insurance companies don’t typically pay for cannabis. Although medical marijuana is federally regulated it is not an approved medicine in Canada and has no Drug Identification Number (DIN).

But Zaid wouldn’t give up. He was frustrated with always asking his parents for money to buy his “medicine” from a licensed producer. And after trying 48 different drugs over the years, only marijuana eased his chronic headaches. He figured it should be recognized as prescription medication — after all, it was prescribed by a doctor.

Zaid, the son of a retired lawyer, presented research on his condition and the medicinal benefits of marijuana to an oversight committee of the University of Waterloo student union, which administers the student health plan. It would be up to the student association as the plan’s sponsor — that’s the organization or employer that sets up the healthcare plan — to ask Sun Life to make an exception.

Student Ben Balfour, who is part of the committee, says there was initial concern about approving Zaid’s request because it was their first time dealing with marijuana.

“We were testing the waters and we didn’t know how people would react,” says Balfour, vice-president of operations and finance for the Federation of Students.

But after much back and forth between Zaid and the committee, which includes a physician, his request was approved in December. The committee found Zaid’s evidence to be persuasive, that the plan could support the cost and that having Zaid’s medicinal marijuana covered would positively impact his academic success and wellbeing.

“It’s really something new and I was very excited to be a part of it,” says Balfour. “I’m just very glad that we were able to figure it all out in the end.”

Sun Life issued a cheque reimbursing Zaid for nearly $3,000, covering the costs of cannabis and a $750 vaporizer — he gave the money to his parents. His triumph doesn’t mean other U of W students are automatically covered for medicinal marijuana, which has not been added to the formulary. But, it opens the door for others to follow his lead and go through the same process.

Sun Life can’t comment on the specifics of this case or benefit plan. While medical marijuana is not an eligible expense in its standard benefit plans, Sun Life does consider requests for exceptions if directed by the organization or employer responsible for the benefit plan. Insurance behemoth Manulife has a similar policy, but is not aware of having made any exception for medical cannabis.

There are cases of the government paying for medical marijuana: Ontario’s Workplace Safety and Insurance Board (WSIB), Quebec’s Commission de la santé et de la sécurité du travail (CSST), and Veterans Affairs, via

Medavie Blue Cross, have covered cannabis costs.

It’s unclear how unusual Zaid’s case is because Sun Life will not comment on if other patients, or benefit plans, have requested similar coverage.

And, it’s unknown what effect, if any, it will have on future claims for cannabis made to insurers, says Wendy Hope, vice-president of external relations for the Canadian Life and Health Insurance Association. Hope says this sort of claim is not unprecedented and that some private insurers have, for some time now, been reimbursing costs for medical marijuana through health spending accounts – although it is rare.

Zaid attributes his success to not giving up, but realizes few patients have the strength, or know-how, to accomplish what he did.

“We’re talking about very sick people and lots of them don’t have the resources to spend in order to fight for fair access,” says Zaid. His advocacy work prompted him to launch the non-profit Canadians for Fair Access to Medical Marijuana and he now sits on the patient advisory board of licensed producer Bedrocan Canada.

Sarah Smith, who pays $180 a month out-of-pocket for medical cannabis after being denied by her private insurer, hopes Zaid’s case will impact insurance practices. Unlike Zaid, she says, “I didn’t have the fight in me.”

“I’m optimistic this will help open the eyes of insurance companies that not all prescriptions are pills, sometimes it’s an herb,” says Smith, not her real name. “They shouldn’t be differentiating — a prescription is a prescription.”

Zaid’s case is precedent-setting, says Marc Wayne, CEO of Bedrocan Canada and chair of the Canadian Medical Cannabis Industry Association.

“It’s an example of the way this type of thing has to work. . . Insurance companies aren’t going to come out and say, ‘We’re going to cover medicinal cannabis for everybody.’ It’s a case-by-case approach and hopefully it will reach a tipping point.”

Source: http://www.thestar.com/life/health_wellness/2015/03/20/private-insurer-covers-medical-marijuana-costs.html

Enertopia Announces V-LOVE ™ For Women

Posted by AGORACOM-JC at 8:07 AM on Monday, February 9th, 2015

VANCOUVER, BC / Enertopia Corporation (ENRT-OTCBB) (TOP-CSE) (the “Company” or “Enertopia”) is pleased to announce the launch of a new product line for women’s sexual health. This is the Company’s first step in its new initiatives and strategic plan in alternative health and wellness sector. V-LoveTM for Women is a desire gel and will be available for sale in Canada soon and will be available for sale in the USA later this year. The Company owns 100% of the product and how it will roll out the product to market.

The Company has entered into a partnership with Maureen McGrath, host of the popular Sunday Night Sex Show on CKNW radio, to raise awareness and continue to educate the public with her knowledge base and expertise in Men’s and Women’s sexual health. Maureen McGrath is a registered nurse in the field of sexual health for men and women.

Enertopia will be announcing additional information on its product lines and business plan in the immediate future as it launches its products in a growing sexual health market with industry sales that have surpassed $20 billion dollars and specifically over $1.2 billion dollars last year in the lubrication market alone. The first product launch V-Love will be in Canada and available in the United States in the coming months. The second product launch will be the V-LoveTM infused with CBD from industrial hemp oil made and only available in the USA. Our goal is to begin producing cash flows from these initiatives as soon as possible; focused on the immediate opportunities in the CBD-sectors derived from already-legal hemp. CBDs (Cannabidiols) have been found by many researchers to have antioxidant properties and are able to be infused into a number of products.

The US Federal government, through the US Department of Health and Human Services, owns US Patent #6,630,507, which among other things, claims that

“Cannabinoids have been found to have antioxidant properties, unrelated to NMDA receptor antagonism. This new found property makes cannabinoids useful in the treatment and prophylaxis of wide variety of oxidation associated diseases, such as ischemic, age-related, inflammatory and autoimmune diseases.”

Maureen is a clinician in addition to being well known and sought after guest lecturer in the field of sexual health for men and women. She has a special interest in women’s sexual desire. This aligns with our vision for natural based healing options. Maureen’s passion over the past two decades of learning and responding to her patient’s needs has led to natural based healing as a clear option for better health in many instances. She is in private practice both in North Vancouver and at Cross Roads Clinic in Vancouver where she see patients with sexual health issues.

“I am excited at the prospect of raising awareness and providing options about such an important subject as female and male sexuality. Providing evidence based strategies to patients is the cornerstone to getting people to feel comfortable discussing a subject that until now has been deemed very sensitive by many. Getting couples to live their life, their way is what this is all about,” said Maureen McGrath, RN and Sexpert.

During the Company’s research in the Medical Marijuana field and other parallel industries it has become apparent that proper education is paramount for people to regain their lives. “Everyone has to be their own personal advocate for better health.” Stated President / CEO Robert McAllister

For further information please visit the company’s updated website www.enertopia.com that has incorporated today’s news and the new Health Canada guidelines for Licensed Producers and those in the process of becoming a licensed producer on what can be shown on one’s website or printed materials.

About Enertopia

Enertopia’s shares are quoted in Canada with symbol TOP and in the United States with symbol ENRT. For additional information, please visit www.enertopia.com or call Robert McAllister, the President: (250) 765-6412

This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, potential and financing of its medical marihuana projects, evaluation and sale of sexual creams and other items, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions that are forward-looking statements. Such forward-looking statements are estimates reflecting the Company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements., foreign exchange and other financial markets; changes of the interest rates on borrowings; hedging activities; changes in commodity prices; changes in the investments and exploration expenditure levels; litigation; legislation; environmental, judicial, regulatory, political and competitive developments in areas in which Enertopia Corporation operates. The User should refer to the risk disclosures set out in the periodic reports and other disclosure documents filed by Enertopia Corporation from time to time with regulatory authorities. There is no assurance that Maureen McGrath’s outreach or the V-LoveTM sexual gel will have any meaningful impact on the Company or the Company will be able to obtain future financings.

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release

Start your small cap medical marijuana research in the AGORACOM Small Cap 
Medical Marijuana Stocks Gateway: 
http://agoracom.com/portal/Small%20Cap%20Medical%20Marijuana%20Stocks

Legal Marijuana is Now the Fastest Growing Industry in America

Posted by AGORACOM-JC at 1:16 PM on Tuesday, January 27th, 2015

Legal Marijuana is Now the Fastest Growing Industry in America

Indulging in the green is no longer just a cocktail conversation – it’s big business.

According to researchers from cannabis industry investment and research firm The ArcView Group, the legal marijuana market in the United States ballooned to $2.7 billion last year, growing 74 per cent from 2013 to become the fastest-growing industry in the nation.

That’s a lot of weed sales – and a major boost to the economy business leaders are all of a sudden taking very seriously.

Just ask former US Senator Mike Gravel.

What’s especially impressive is only four states have legalized adult cannabis use and sales, with another eight expected to jump on board by the end of next year.

If legalization is eventually enacted across all 50 states, the legal marijuana industry is projected to become larger than the organic food industry.

And while the U.S. is blazing the trail, we can probably expect a budding cannabis business to boost Canada’s GDP in the near future – Trudeau 2015, anyone? After all, everything that happens in the U.S. eventually becomes big North of the Border.

Who would have guessed that the most effective recovery from the next recession could be to smoke ourselves out?

Certainly not what we learned in economics class.

#NOTABLE

Want more updates on the most Notable things happening so you know before your colleagues do? Get our exclusive newsletter here and follow us on Twitter for all the latest.

Source: http://notable.ca/nationwide/yp-life/Legal-Marijuana-is-Now-the-Fastest-Growing-Industry-in-America/

Start your small cap medical marijuana research in the AGORACOM Small Cap 
Medical Marijuana Stocks Gateway: 
http://agoracom.com/portal/Small%20Cap%20Medical%20Marijuana%20Stocks

Mazorro Receives Conditional Approval of Change of Business and Name Change

Posted by AGORACOM-JC at 4:36 PM on Wednesday, December 3rd, 2014

OTTAWA, ONTARIO–(Dec. 3, 2014) – Mazorro Resources Inc. (the “Company“) (CSE:MZO)(FRANKFURT:JAM) announces that it has received the conditional approval of the Canadian Securities Exchange (the “CSE“) for its proposed change of business from mineral resource exploration to the medical marijuana industry (the “Change of Business“) and its change of name to “GrowPros Cannabis Inc. / Entreprise GrowPros cannabis inc.” (the “Name Change“) upon receipt of necessary shareholder approval in respect thereof and completion of the three-cornered amalgamation with GrowPros MMP Inc., previously announced on November 6, 2014 (the “Amalgamation“).

The Company has filed an updated Form 2A listing statement under its profile on the CSE website and on SEDAR at www.sedar.com that provides additional disclosure of the terms of the Amalgamation, the Company’s proposed new business, and the related risk factors.

The Company expects that the CSE will publish a bulletin shortly to announce the resumption of trading of the Company’s common shares (the “Common Shares“) on the CSE at the opening of trading on December 4, 2014. The trading symbol “MZO” will remain the same until completion of the Amalgamation and the Name Change, following which the Common Shares will trade on the CSE under the symbol “GCI”.

Completion of the Amalgamation, the Change of Business, and the Name Change, remain subject to a number of conditions, including, but not limited to, receipt of necessary shareholder approvals in respect thereof and satisfaction of standard closing conditions for transactions of this nature.

The special meeting of the Company’s shareholders that was called to seek the requisite approval for the Change of Business and the Name Change, among other items, has been postponed and will now be held on December 29, 2014 (the “Special Meeting“). A notice of meeting, management information circular, and form of proxy in respect of the Special Meeting will be sent to shareholders and is available under the Company’s profile on the CSE website and on SEDAR.

The Canadian Securities Exchange (CSE) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to complete the Amalgamation and Change of Business, failure to obtain sufficient financing, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Any forward-looking statement speaks only as of the date on which it is made and except as may be required by applicable securities laws. The Company disclaims any intent or obligation to update any forward-looking statement.

Mazorro Resources Inc.
Andre Audet
Interim President, CEO, and CFO
(613) 241-2332